Tarpley E L
Pharmacotherapy. 1982 Sep-Oct;2(5):281-4. doi: 10.1002/j.1875-9114.1982.tb03199.x.
Thirty-five patients whose hypertension was not adequately controlled with optimum doses of hydrochlorothiazide (50-200 mg) entered a long-term study to evaluate the efficacy, safety, and tolerability of oxprenolol hydrochloride (60-480 mg). All patients were included in the analysis of safety and tolerability, while the data of 26 patients studied for at least 22 months were used for a parametric analysis of efficacy. Mean standing systolic/diastolic blood pressure was significantly (p less than 0.001) reduced from 171/106 mm Hg to 142/85 mm Hg within three weeks of treatment. There was a similar reduction in supine blood pressure. All 26 patients were normotensive at the end of the titration period and blood pressure control was maintained for at least 22 months of therapy. Oxprenolol produced no serious adverse effects. The results of this long-term study suggest that oxprenolol is effective, well tolerated, and safe in the treatment of thiazide-resistant hypertension.
35例使用最佳剂量氢氯噻嗪（50 - 200毫克）但高血压控制不佳的患者进入一项长期研究，以评估盐酸氧烯洛尔（60 - 480毫克）的疗效、安全性和耐受性。所有患者均纳入安全性和耐受性分析，而对26例研究至少22个月的患者的数据进行疗效参数分析。治疗三周内，平均站立收缩压/舒张压从171/106毫米汞柱显著（p小于0.001）降至142/85毫米汞柱。仰卧血压也有类似下降。在滴定期结束时，所有26例患者血压均正常，且在至少22个月的治疗中血压控制得以维持。盐酸氧烯洛尔未产生严重不良反应。这项长期研究结果表明，盐酸氧烯洛尔在治疗噻嗪类抵抗性高血压方面有效、耐受性良好且安全。
